Research & Literature

Differentiation between Graves' disease and painless thyroiditis by diffusion-weighted imaging, thyroid iodine uptake, thyroid scintigraphy and serum parameters.

Meng Z, Zhang G, Sun H, et al.

Experimental and therapeutic medicine 2015; (9(6)):2165-2172 doi:10.3892/etm.2015.2430.

Management of Graves Disease: A Review.

Burch HB, Cooper DS

JAMA 2015; (314(23)):2544-54 doi:10.1001/jama.2015.16535.

Pretibial Myxedema Masquerading as a Venous Leg Ulcer.

Herskovitz I, Hughes O, MacQuhae F, Kirsner RS

Wounds : a compendium of clinical research and practice 2017; (29(3)):77-79.

Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance.

Bucci I, Giuliani C, Napolitano G

Frontiers in endocrinology 2017; (8()):137 doi:10.3389/fendo.2017.00137.

Hyperthyroidism and the Heart.

Osuna PM, Udovcic M, Sharma MD

Methodist DeBakey cardiovascular journal 2017; (13(2)):60-63 doi:10.14797/mdcj-13-2-60.

Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.

Rotondi M, Molteni M, Leporati P, et al.

Frontiers in endocrinology 2017; (8()):254 doi:10.3389/fendo.2017.00254.

Preoperative management in patients with Graves' disease.

Piantanida E

Gland surgery 2017; (6(5)):476-481 doi:10.21037/gs.2017.05.09.

Treatment choice, satisfaction and quality of life in patients with Graves' disease.

Conaglen HM, Tamatea JAU, Conaglen JV, Elston MS

Clinical endocrinology 2018; (88(6)):977-984 doi:10.1111/cen.13611.

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.

Pariani N, Willis M, Muller I, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(8)):3010-3018 doi:10.1210/jc.2018-00359.

The effect of oral statin therapy on strabismus in patients with thyroid eye disease.

Reynolds AL, Del Monte MA, Archer SM

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2018; (22(5)):340-343 doi:10.1016/j.jaapos.2018.04.009.

Treatment of adult Graves' disease.

Corvilain B, Hamy A, Brunaud L, et al.

Annales d'endocrinologie 2018; (79(6)):618-635 doi:10.1016/j.ando.2018.08.003.

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study.

Karmisholt J, Andersen SL, Bulow-Pedersen I, et al.

Journal of thyroid research 2019; (2019()):5945178 doi:10.1155/2019/5945178.

Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients.

Vita R, Di Bari F, Perelli S, et al.

Journal of clinical & translational endocrinology 2019; (15()):65-69 doi:10.1016/j.jcte.2019.01.001.

Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.

Okosieme OE, Taylor PN, Evans C, et al.

The lancet. Diabetes & endocrinology 2019; (7(4)):278-287 doi:10.1016/S2213-8587(19)30059-2.

Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.

Zeng P, Fan SX, Li ZJ, et al.

Journal of ophthalmology 2019; (2019()):7602419 doi:10.1155/2019/7602419.

Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial.

Azizi F, Takyar M, Madreseh E, Amouzegar A

Pediatrics 2019; (143(5)) doi:10.1542/peds.2018-3034.

Thyrotoxic hypokalemic periodic paralysis due to Graves' disease in 2 adolescents.

Roh JG, Park KJ, Lee HS, Hwang JS

Annals of pediatric endocrinology & metabolism 2019; (24(2)):133-136 doi:10.6065/apem.2019.24.2.133.

Salt iodization halves risk of thyrotoxicosis in Denmark.

Zimmermann MB

Nature reviews. Endocrinology 2019; (15(11)):632-633 doi:10.1038/s41574-019-0261-z.

Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy.

Bobanga ID, McHenry CR

Best practice & research. Clinical endocrinology & metabolism 2019; (33(4)):101319 doi:10.1016/j.beem.2019.101319.

Role of Maternal Thyroid-Stimulating Immunoglobulin in Graves' Disease for Predicting Perinatal Thyroid Dysfunction.

Cui Y, Rijhsinghani A

AJP reports 2019; (9(4)):e341-e345 doi:10.1055/s-0039-1694035.

The Effect of Smoking on Mitochondrial Biogenesis in Patients With Graves Ophthalmopathy.

Yuksel N, Yaman D, Tugce Pasaoglu O, Pasaoglu H

Ophthalmic plastic and reconstructive surgery 2020; (36(2)):172-177 doi:10.1097/IOP.0000000000001514.

First tracheal ring fracture in a complex thyroid surgery.

Husain R, Alnasser A, Al Duhileb M, Madkhali T

International journal of surgery case reports 2020; (66()):309-312 doi:10.1016/j.ijscr.2019.12.012.

Radioiodine therapy and Graves' disease - Myths and reality.

Plazinska MT, Sawicka-Gutaj N, Czarnywojtek A, et al.

PloS one 2020; (15(1)):e0226495 doi:10.1371/journal.pone.0226495.

CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY.

Jariyawattanarat V, Sungkanuparph S, Sriphrapradang C

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(6)):612-618 doi:10.4158/EP-2019-0514.

TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.

Kahaly GJ, Diana T, Olivo PD

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(1)):97-106 doi:10.4158/EP-2019-0363.

Ocular conditions and dry eye due to traditional and new forms of smoking: A review.

Makrynioti D, Zagoriti Z, Koutsojannis C, et al.

Contact lens & anterior eye : the journal of the British Contact Lens Association 2020; (43(3)):277-284 doi:10.1016/j.clae.2020.02.009.

Graves Disease With Thyroid-Stimulating Hormone Receptor-Blocking Autoantibodies During Pregnancy.

Decallonne B, Martens PJ, Van den Bruel A, et al.

Annals of internal medicine 2020; (172(11)):767-769 doi:10.7326/L19-0818.

Hyperthyroidism.

McDermott MT

Annals of internal medicine 2020; (172(7)):ITC49-ITC64 doi:10.7326/AITC202004070.

Current controversies in the management of Graves' hyperthyroidism.

Francis N, Francis T, Lazarus JH, Okosieme OE

Expert review of endocrinology & metabolism 2020; (15(3)):159-169 doi:10.1080/17446651.2020.1754192.

Surgical treatment of children Graves' disease with huge goiter-a case report and literature review.

Li Y, Cui X, Yang Y, et al.

Gland surgery 2020; (9(2)):467-473 doi:10.21037/gs.2020.02.19.

Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti‑TSHR immunoassay for Graves' disease: a Chinese multicenter study.

Cheng X, Chai X, Ma C, et al.

Endocrine 2021; (71(1)):139-148 doi:10.1007/s12020-020-02386-2.

SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19.

Mateu-Salat M, Urgell E, Chico A

Journal of endocrinological investigation 2020; (43(10)):1527-1528 doi:10.1007/s40618-020-01366-7.

Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis.

Perdomo CM, García-Goñi M, Sancho L, et al.

Clinical endocrinology 2021; (94(3)):466-472 doi:10.1111/cen.14308.

New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report.

Yamada H, Okajima F, Onda T, et al.

BMC endocrine disorders 2020; (20(1)):132 doi:10.1186/s12902-020-00613-5.

Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease.

Varma A, Rheeman C, Levitt J

JAAD case reports 2020; (6(12)):1281-1282 doi:10.1016/j.jdcr.2020.09.003.

Short-Term Outcomes of Surgery for Graves' Disease in Germany.

Maurer E, Vorländer C, Zielke A, et al.

Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9124014.

Graves' Disease Presenting with Complete Atrioventricular Block.

Eom YS, Oh PC

Case reports in endocrinology 2020; (2020()):6656875 doi:10.1155/2020/6656875.

Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy.

Smith TJ

European thyroid journal 2020; (9(Suppl 1)):31-39 doi:10.1159/000507992.

Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies.

Stöhr M, Oeverhaus M, Lytton SD, et al.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2021; (53(4)):235-244 doi:10.1055/a-1373-5523.

Risk Factors of Thyroid Eye Disease.

Lee MH, Chin YH, Ng CH, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(3)):245-253 doi:10.1016/j.eprac.2020.11.011.

Teprotumumab: The First Approved Biologic for Thyroid Eye Disease.

Hwang CJ, Eftekhari K

International ophthalmology clinics 2021; (61(2)):53-61 doi:10.1097/IIO.0000000000000353.

Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.

Chern A, Dagi Glass LR, Gudis DA

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2021; (165(6)):757-758 doi:10.1177/01945998211004240.

The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea.

Park SY, Kim BH, Kim M, et al.

Endocrine 2021; (74(1)):120-127 doi:10.1007/s12020-021-02725-x.

A case of thyroid storm caused by Graves' disease misdiagnosed as panic attack due to panic disorder.

Yasuda M, Kumakura J, Oka K, Fukuda K

BioPsychoSocial medicine 2021; (15(1)):11 doi:10.1186/s13030-021-00211-4.

Insidious-Onset Indurated Plaques on the Shins.

Agrawal R, Knabel D, Fernandez AP

Dermatopathology (Basel, Switzerland) 2021; (8(2)):185-189 doi:10.3390/dermatopathology8020024.

Ototoxicity and Teprotumumab.

Highland J, Gordon S, Reddy D, Patel N

The Annals of otology, rhinology, and laryngology 2022; (131(8)):910-913 doi:10.1177/00034894211042740.

Incidence, risk factors, natural history and outcomes of heart failure in patients with Graves' disease.

Naser JA, Pislaru S, Stan MN, Lin G

Heart (British Cardiac Society) 2022; (108(11)):868-874 doi:10.1136/heartjnl-2021-319752.

De Novo Extra-Thyroidal Manifestations of Graves' Disease presenting 16 Years after Total Thyroidectomy for Thyroid Cancer.

Kwee A, Yong KL, Seah LL, Chng CL

Journal of the ASEAN Federation of Endocrine Societies 2021; (36(2)):216-219 doi:10.15605/jafes.036.02.08.

Hyperthyroidism in Graves Disease Causes Sleep Disorders Related to Sympathetic Hypertonia.

Matsumoto K, Izawa S, Fukaya K, et al.

The Journal of clinical endocrinology and metabolism 2022; (107(5)):e1938-e1945 doi:10.1210/clinem/dgac013.

The Unlikely Suspect: A Case Report of New-Onset Hyperthyroidism Due to Graves' Disease in an 89-Year-Old Gentleman and Review of Literature.

Sharma P

Cureus 2022; (14(1)):e21546 doi:10.7759/cureus.21546.

Thyrotoxic myopathy: research status, diagnosis, and treatment.

Cui H, Zhang X

Endokrynologia Polska 2022; (73(1)):157-162 doi:10.5603/EP.a2022.0004.

Hemodynamic variation is a dominant contributing factor of Graves' hyperthyroidism complication: Heart failure and fatal liver dysfunction, a case report and analysis.

Li Z, Wang J, Zeng J, et al.

Clinical case reports 2022; (10(2)):e05289 doi:10.1002/ccr3.5289.

Pathophysiology of thyroid-associated orbitopathy.

Lee ACH, Kahaly GJ

Best practice & research. Clinical endocrinology & metabolism 2023; (37(2)):101620 doi:10.1016/j.beem.2022.101620.

Alemtuzumab-Induced Autoimmune Thyroid Dysfunction.

Ragavan S, Elhelw O, Majeed W, et al.

Cureus 2022; (14(3)):e22751 doi:10.7759/cureus.22751.

Magnetic resonance imaging in thyroid eye disease: Signal intensity ratio to measure disease activity.

Rath S

Indian journal of ophthalmology 2022; (70(5)):1446-1447 doi:10.4103/ijo.IJO_365_22.

Histopathological Evidence of Thyroid Dermopathy and its Correlation with Thyroid-Associated Orbitopathy in Patients with Graves' Disease having Normally Appearing Pretibial Skin: A Case-Control Study.

Mishra A, Chakraborty PP, Jana S, et al.

Indian journal of endocrinology and metabolism 2022; (26(2)):141-148 doi:10.4103/ijem.ijem_504_21.

Study of the Associations between Color Doppler Ultrasound Grading of Hyperthyroidism and Biochemical Data on Thyroid Function.

Zhang L, Li J, Zhang S, et al.

International journal of endocrinology 2022; (2022()):9743654 doi:10.1155/2022/9743654.

Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease.

Ma EZ, Kuo JH, Malek R, et al.

Surgery 2023; (173(1)):193-200 doi:10.1016/j.surg.2022.06.044.

Lower limb pain and edema due to thyroid dermopathy: an unusual presentation of Graves disease in an adolescent patient.

Berlingieri DM, Moras LA, Scliar C

Archivos argentinos de pediatria 2023; (121(2)):e202202615 doi:10.5546/aap.2022-02615.eng.

Smoking Is Associated With a Higher Risk of Surgical Intervention for Thyroid Eye Disease in the IRIS Registry.

Oke I, Reshef ER, Elze T, et al.

American journal of ophthalmology 2023; (249()):174-182 doi:10.1016/j.ajo.2023.01.020.

Immune checkpoint inhibitor-related thyroid dysfunction.

Illouz F, Briet C, Rodien P

Annales d'endocrinologie 2023; (84(3)):346-350 doi:10.1016/j.ando.2023.03.005.

Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease.

Perros P, Žarković M, Pearce SH, et al.

American journal of ophthalmology 2023; (252()):94-100 doi:10.1016/j.ajo.2023.03.027.

Transit analysis of thyroid antibodies in graves' disease following painless thyroiditis: a case report.

Suto D, Ebihara K, Ishikawa SE

Annals of medicine and surgery (2012) 2023; (85(5)):2119-2122 doi:10.1097/MS9.0000000000000543.

Third-Generation Thyrotropin Receptor Antibody (TRAb) assay for predicting neonatal thyroid dysfunction in pregnant women with Graves' disease.

Priyanka R, Sridhar S, Sumathi B, et al.

Endocrine 2024; (84(2)):500-508 doi:10.1007/s12020-023-03569-3.

Teprotumumab for Treatment of Pretibial Myxedema.

Reyes MP, Cabrera J, Singh J, Turnbull D

JCEM case reports 2023; (1(1)):luac037 doi:10.1210/jcemcr/luac037.

Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.

Men CJ, Amarikwa L, Pham B, et al.

Ophthalmic plastic and reconstructive surgery 2024; (40(3)):276-285 doi:10.1097/IOP.0000000000002564.

Teprotumumab and Orbital Decompression for the Management of Proptosis in Patients With Thyroid Eye Disease.

Hubschman S, Sojitra B, Ghiam S, et al.

Ophthalmic plastic and reconstructive surgery 2024; (40(3)):270-275 doi:10.1097/IOP.0000000000002563.

Autoimmune Thyroid Diseases.

Petranović Ovčariček P, Görges R, Giovanella L

Seminars in nuclear medicine 2024; (54(2)):219-236 doi:10.1053/j.semnuclmed.2023.11.002.

Hyperthyroidism.

Chaker L, Cooper DS, Walsh JP, Peeters RP

Lancet (London, England) 2024; (403(10428)):768-780 doi:10.1016/S0140-6736(23)02016-0.

Association between thymic hyperplasia and serum calcium level in Graves' disease.

Zeng J, Li L, Wei D

BMC endocrine disorders 2024; (24(1)):15 doi:10.1186/s12902-024-01541-4.

Graves' disease thyroid dermopathy: a case report.

Tashkandi L, Alsagheir A, Alobaida S, Alhuthil R

Journal of medical case reports 2024; (18(1)):164 doi:10.1186/s13256-024-04462-x.

Management of fetal hyperthyroidism caused by persistent autoimmune antibodies in a case of previously treated maternal Graves' disease.

Karri SR, Roy PS, Nandi N, et al.

Obstetric medicine 2024; (17(2)):108-111 doi:10.1177/1753495X221146340.

A Rare and Unusual Evolution of Hypothyroidism in Hashimoto's Thyroiditis to Graves' Disease: A Case Report and Literature Review.

Essouabni A, Melki FZ, Essafi MA, et al.

Cureus 2024; (16(4)):e59059 doi:10.7759/cureus.59059.

Orbital decompression following treatment with teprotumumab for thyroid eye disease.

Topilow NJ, Penteado RC, Ting M, et al.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2025; (60(1)):e59-e64 doi:10.1016/j.jcjo.2024.06.003.

Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series.

Ugradar S, Parunakian E, Malkhasyan E, et al.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(1)):225-230 doi:10.1007/s00417-024-06599-3.

A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the FDA Adverse Event Reporting System.

Huynh PP, Saba E, Rivero A, et al.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2024; (45(8)):e566-e569 doi:10.1097/MAO.0000000000004260.

Assessment of CD40L and TSAB serum level in Graves disease patients.

Jawad AT, Fahad HM, Salih AA

Human antibodies 2025; (33(3-4)):63-67 doi:10.3233/HAB-240036.

Advances of IGF-1R inhibitors in Graves' ophthalmopathy.

Wang M, Liu L

International ophthalmology 2024; (44(1)):435 doi:10.1007/s10792-024-03358-5.

Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis.

Markle JC, Johanis A, Shaia JK, et al.

Eye (London, England) 2025; (39(6)):1107-1114 doi:10.1038/s41433-024-03531-1.

Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease.

Peng R, Xie P, Jin Z, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(9)):e3002-e3010 doi:10.1210/clinem/dgae892.

Thyrotoxic Hypokalemic Periodic Paralysis Induced by High-Dose Insulin in an Adolescent Male with Type 1 Diabetes Mellitus.

Bayrak Demirel O, Koc C, Tercan U, et al.

Hormone research in paediatrics 2024; 1-5 doi:10.1159/000543329.

Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease.

Bartalena L, Smith TJ

The Journal of clinical endocrinology and metabolism 2025; (110(4)):922-930 doi:10.1210/clinem/dgaf009.

Extent of Surgery in the Surgical Treatment of Graves' Disease: Subtotal vs. Total Thyroidectomy and Comparison of the Long-term Results.

Sengun B, Iscan Y, Sormaz IC, et al.

Sisli Etfal Hastanesi tip bulteni 2024; (58(4)):411-416 doi:10.14744/SEMB.2024.74829.

Non-parathyroid hypercalcemia in a patient with new-onset hyperthyroidism and silicone-induced granulomas: case report.

Montefusco L, Rossi G, Petria I, et al.

Frontiers in endocrinology 2024; (15()):1447652 doi:10.3389/fendo.2024.1447652.

De novo Graves' thyroid eye disease after radioiodine treatment for toxic nodular thyroid disease.

Sankar A, Singh R, Pearce S

BMJ case reports 2025; (18(2)) doi:10.1136/bcr-2024-263986.

Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.

de Souza MVR, Sapienza MT, Brito LP, et al.

Journal of the Endocrine Society 2025; (9(3)):bvaf016 doi:10.1210/jendso/bvaf016.

Otologic Symptoms Following Teprotumumab Administration in Patients with Thyroid Eye Disease.

Epperson MV, Hughes S, Valenzuela CV, Stucken EZ

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2025; (46(3)):330-335 doi:10.1097/MAO.0000000000004418.

Prepubertal Graves' disease with hyperactivity and overgrowth since early childhood.

Park J, Kanda J, Takahashi K, Tanaka H

BMJ case reports 2025; (18(3)) doi:10.1136/bcr-2025-264935.

Factors Associated with Response to Intravenous Glucocorticoids in Active Moderate-to-Severe Thyroid Eye Disease.

Baczewska N, Alexopoulou O, Constantinescu SM, et al.

Thyroid : official journal of the American Thyroid Association 2025; (35(4)):424-432 doi:10.1089/thy.2024.0629.

Remission of Graves' Disease Through Lifestyle Interventions.

Sharma P

Cureus 2025; (17(4)):e81900 doi:10.7759/cureus.81900.

Unilateral Graves' Disease With Ipsilateral Papillary Thyroid Cancer: A Case Report.

Alqattan MH, Alqadhi MA, Alawadh AM, et al.

Cureus 2025; (17(3)):e80998 doi:10.7759/cureus.80998.

Performance of the Siemens' thyroid stimulating immunoglobulin assay in the diagnosis of hyperthyroidism: Prospective cohort study.

Kline GA, Proctor DT, Moledina N, et al.

Clinical biochemistry 2025; (137()):110938 doi:10.1016/j.clinbiochem.2025.110938.

Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.

Wiersinga WM, Eckstein AK, Žarković M

The lancet. Diabetes & endocrinology 2025; (13(7)):600-614 doi:10.1016/S2213-8587(25)00066-X.

High maternal serum thyroid-stimulating hormone receptor antibodies with fetal and neonatal thyrotoxicosis after total thyroidectomy for Graves' disease.

Mamah JE, Law H, Prince S, Bodmer C

BMJ case reports 2025; (18(5)) doi:10.1136/bcr-2024-264047.

Assessment of thyroid-associated ophthalmopathy activity using corrected standardised uptake value maximum (SUVmax) and uptake ratios from 99Tcm-diethylene triamine pentaacetic acid single photon emission computed tomography/computed tomography (99Tcm-DTPA SPECT/CT) imaging.

Sun J, Ma L, Wang M, Yuan X

Clinical radiology 2025; (86()):106946 doi:10.1016/j.crad.2025.106946.

TSH Receptor Antibody Test Utilization Patterns From a National Reference Laboratory: TRAb, TSI, or Both?

Nelson HA, Doyle K, Straseski JA

The Journal of clinical endocrinology and metabolism 2025; (111(1)):e92-e99 doi:10.1210/clinem/dgaf330.

Persistent Palmar Rash Associated with Teprotumumab Treatment.

He LR, Villatoro GA, Yen MT

Ophthalmic plastic and reconstructive surgery 2026; (42(1)):e8-e9 doi:10.1097/IOP.0000000000002985.

Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study.

Barnett MJL, Lam J, Jara-Tantoco MN, et al.

Endocrine connections 2025; (14(7)).

Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?

Bartalena L, Gallo D, Kahaly GJ, et al.

Journal of endocrinological investigation 2025; (48(9)):1927-1950 doi:10.1007/s40618-025-02653-x.

Low risk of thyroid eye disease (TED) following radioiodine (RAI) therapy in a multidisciplinary setting: a retrospective cohort study.

Vekinis JS, Clarke K, Lee V, et al.

Thyroid research 2025; (18(1)):41 doi:10.1186/s13044-025-00259-2.

Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction.

Jiao Y, Xu M, Rao X

Frontiers in endocrinology 2025; (16()):1620718 doi:10.3389/fendo.2025.1620718.

Mitigating the risks: addressing smoking cessation in thyroid eye disease.

Karimi N, Kashkouli MB, Keyhani A, et al.

BMJ open ophthalmology 2025; (10(1)) doi:10.1136/bmjophth-2025-002226.

Unravelling the pathogenic mechanisms in Graves' orbitopathy.

Lee ACH, Kahaly GJ

European thyroid journal 2025; (14(5)).

High TRAb Titer at Diagnosis Predicts Persistent Positivity and Relapse in Graves' Disease after Prolonged Antithyroid Therapy.

Chen Z, Xu J, Kang W, et al.

Endocrinology and metabolism (Seoul, Korea) 2025; (40(6)):950-960 doi:10.3803/EnM.2025.2405.

Autoimmune Thyroid Disease in Pregnancy: Clinical Implications for Miscarriage Risk.

Shibi Anilkumar A, Mariam Thomas S, Veerabathiran R

Endocrine research 2026; (51(1)):1-14 doi:10.1080/07435800.2025.2575170.

A Trajectory of Thyroid Function: From Thyrotoxic Paralysis to Post-ablative Hypothyroidism.

Anantha Ganesan J, Ekpemandu NM

Cureus 2025; (17(11)):e96924 doi:10.7759/cureus.96924.

Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves' disease: a nested prospective cohort study with propensity score matching.

Suzuki K, Kobayashi T, Izuchi T, et al.

Frontiers in endocrinology 2025; (16()):1701500 doi:10.3389/fendo.2025.1701500.

A TRAb-First Diagnostic Strategy for Overt Hyperthyroidism: Diagnostic Performance and Implications for Reflex Testing.

Petranović Ovčariček P, Campennì A, D'Aurizio F, et al.

Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020445.

The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.

Yuan X, Li H, Wang F

Frontiers in medicine 2026; (13()):1758015 doi:10.3389/fmed.2026.1758015.

Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety.

Song R, Zhao W, Li S, et al.

Frontiers in endocrinology 2026; (17()):1735660 doi:10.3389/fendo.2026.1735660.

Updates on Treatment in Thyroid Eye Disease for the Neurologist.

Alryalat SA, Alasheh A, Salim QA, Yaaqba N

Neurologic clinics 2026; (44(2)):321-335 doi:10.1016/j.ncl.2025.12.002.